

# U.S. Consumer Product Safety Commission

## LOG OF TELECONFERENCE

**SUBJECT:** Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes

**DATE:** November 15, 2010

**TIME:** 12:00 p.m. to 2:00 p.m. EST

**ENTRY SOURCE:** Michael A. Babich, HSHS

**COMMISSION REPRESENTATIVES:** Michael Babich (HS), Mary Ann Danello (HS), David DiMatteo (GC), Kent Carlson (HS), Michael Greene (EP), Leslie Patton (HS)

**CHAP Members:** Philip Mirkes (Chair), Bernard Schwetz (Vice-Chair), Chris Gennings, Russ Hauser, Holger Koch, Andreas Kortenkamp.

**NON FEDERAL REPRESENTATIVES:** Members of the public were able to listen to the conference call. A list of names is not available.

### **SUMMARY:**

This was the first teleconference of the 2010 Chronic Hazard Advisory Panel (CHAP) on Phthalates and Phthalate Substitutes. The CHAP previously met in April 2010 and July 2010 at CPSC headquarters in Bethesda, MD. Following the welcome and introductions, Dr. Schwetz, the CHAP's Vice-Chair, led the discussion of general approaches to completing the risk assessment required of the CHAP. There was general agreement among CHAP members that the six phthalates mentioned in the Consumer Product Safety Improvement Act of 2008 (CPSIA), plus several other phthalates, need to be included in the quantitative risk assessment. There was general agreement that the most important health endpoint is the antiandrogenic effects of certain phthalates in exposed *in utero* and during postnatal development. There was also general agreement that a hazard index approach is appropriate for estimating the cumulative effects of phthalates.

The CHAP members discussed several other aspects of the risk assessment including which types of products and exposure scenarios should be included, the relative potencies of different phthalates, the relative merits of median and 95<sup>th</sup> percentile exposures, and whether to include other non-phthalate compounds with antiandrogenic effects. The CHAP members also discussed how to utilize information from "robust summaries" prepared by chemical manufacturers when the toxicity studies are not publicly available. The latter issue applies primarily to phthalate substitutes. The above topics will be discussed again at the December CHAP meeting.

Dr. Mirkes, Chair, led a discussion of a possible approach to analyzing human biomonitoring data, such as National Human Nutrition and Examination Survey (NHANES) data, which was proposed by Drs. Gennings and Koch.

The CHAP will continue its discussion of these topics at a public meeting on December 2-3, 2010 at the CPSC offices in Bethesda, MD.

Additional information on the CHAP is available at:  
<http://www.cpsc.gov/about/cpsia/chapmain.html>